rs748309520
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003119.4(SPG7):c.988-1G>A variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000991 in 1,613,996 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_003119.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPG7 | NM_003119.4 | c.988-1G>A | splice_acceptor_variant | ENST00000645818.2 | NP_003110.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPG7 | ENST00000645818.2 | c.988-1G>A | splice_acceptor_variant | NM_003119.4 | ENSP00000495795 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152222Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250692Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135608
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461774Hom.: 0 Cov.: 31 AF XY: 0.0000124 AC XY: 9AN XY: 727208
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152222Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74354
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 7 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 09, 2023 | For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 7 of the SPG7 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs748309520, gnomAD 0.004%). Disruption of this splice site has been observed in individuals with spastic ataxia (PMID: 26626314). ClinVar contains an entry for this variant (Variation ID: 217270). Studies have shown that disruption of this splice site results in use of cryptic acceptor splice sites and introduces a premature termination codon (PMID: 26626314). The resulting mRNA is expected to undergo nonsense-mediated decay. - |
Pathogenic, criteria provided, single submitter | case-control | Neurogenetics of motion laboratory, Montreal Neurological Institute | - | - - |
Pathogenic, criteria provided, single submitter | research | PROSPAX: an integrated multimodal progression chart in spastic ataxias, Center for Neurology; Hertie-Institute for Clinical Brain Research | Jan 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 17, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 25, 2023 | Variant summary: SPG7 c.988-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes the canonical 3' acceptor site and one predicts the variant creates a cryptic 3' acceptor site 2nt downstream into exon 8. cDNA sequencing of a homozygous patient confirmed that the variant affects mRNA splicing, resulting in 2 alternatively spliced transcripts: one transcript uses the newly created cryptic 3' acceptor site 2nt into exon 8, and a second transcript uses a different cryptic 3' acceptor site 21nt into exon 8 (Choquet_2016). The variant allele was found at a frequency of 1.6e-05 in 250692 control chromosomes (gnomAD). c.988-1G>A has been reported in the literature as a biallelic genotype in multiple individuals affected with Hereditary Spastic Paraplegia (Choquet_2016, Almomen_2019, Sun_2019). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 30747022, 26626314, 29915382). Three ClinVar submitters have assessed the variant since 2014: all three classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Hereditary spastic paraplegia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Apr 16, 2021 | - - |
SPG7-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 19, 2023 | The SPG7 c.988-1G>A variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in the homozygous and compound heterozyous state in individuals with spastic paraplegia phenotypes (Choquet et al. 2016. PubMed ID: 26626314; Table 1, Sun et al. 2018. PubMed ID: 29915382; Almomen et al. 2019. PubMed ID: 30747022). Functional splicing studies have also confirmed this variant impacts splicing leading to a frameshift and premature protein termination (Choquet et al. 2016. PubMed ID: 26626314). This variant is reported in 0.0035% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at